For a better understanding of the pathophysiology and mechanisms of phenotypic diversity of sickle cell disease, and for the improvement of its management globally, there is a strong case for developing sustainable research partnerships between rich and poor countries.
Introduction
The inherited disorders of hemoglobin, notably sickle cell (SS) disease and the thalassemias, are the commonest monogenic diseases. As the result of intense selection due to heterozygote advantage against severe forms of malaria they reach particularly high frequencies in many tropical countries and in any populations in which there are large immigrant populations from these regions. Many of the developing countries are passing through an epidemiological transition in which, due to improved nutrition and control of infectious disease, childhood mortality rates are falling. Under these circumstances, the prevalence of genetic disorders like hemoglobinopathies tends to increase; affected children, who would previously have died in the first few years of life, are now surviving long enough to present for diagnosis and treatment. Hence these diseases are presenting an increasingly serious global health problem 1 
.
Although there have been improvements in the management of SS disease leading to longer survival in the developed countries, much remains to be learnt about its pathophysiology and the mechanisms for its clinical diversity. Much less progress has been made in the developing countries in which the disease is common, where it is still an important cause of childhood mortality. We argue here that, both for furthering research and improving clinical care globally, there is a major case for For personal use only. on . by guest www.bloodjournal.org From 3 developing long-term partnerships between research groups working on this disease in the rich and poor countries.
The extent of the problem
Based on heterozygote frequencies SS disease occurs widely throughout subSaharan Africa, parts of the Middle East and, in a patchy distribution, the Indian subcontinent [1] [2] [3] . It also occurs in some European populations, notably Greece and Italy, and at a variable frequency in countries in which there have been major population movements from Africa; USA, Brazil and many countries of the Caribbean and Central America, for example. In many of these populations heterozygote rates range from 5-25% but in certain regions, localized areas of Saudi Arabia for example, up to 40% or more of the population may be carriers. There have been some genuine advances in the symptomatic management of SS disease. A reduction in mortality has been achieved in childhood by the use of prophylactic penicillin 11 and in adults by the administration of hydroxyurea 12 , and it has been established that the frequency of strokes can be reduced by transfusion 13 .
Bone marrow transplantation has also shown limited success, although its role in this disease is not yet clearly defined 14 . However, the place for these approaches, and their potential cost, in the developing countries is not clear.
The Scientific Case for International Collaboration
As knowledge of the pathophysiology of SS disease has accumulated it has become apparent that the basic genetic defect, that is the increased capacity for Hb S to polymerize, is only the tip of the iceberg of the widespread secondary pathology which is responsible for its complex phenotype. This includes an increased facility for sickle red cells to adhere to vascular endothelium, widespread rheologic and hemodynamic changes, endothelial damage and altered flow, platelet activation, abnormal cytokine response, and a variety of other changes 15 . Thus although factors which modify the rate of polymerization of Hb S may be important it is quite likely that many of the most serious complications of the disease result from either environmental or genetic factors which act 'downstream' from the primary genetic defect.
Given this level of complexity it is not surprising that it has been difficult to achieve an agreed classification of the different degrees of severity of SS disease.
For personal use only. on . by guest www.bloodjournal.org From Regardless of the inevitable deficiencies of any classification of this kind it is vital to attempt to produce a workable description of severity as a prelude to the potential international collaborations outlined below.
The central problem which needs addressing, and one which can only be achieved by international collaboration, is the relative roles of the environment and the genome in the clinical diversity of SS disease. Remarkably, there are still no twin or sibling-pair data which address this critical issue. Preliminary enquiries indicate that none of the rich countries have sufficient numbers of twin pairs to carry out a study of this type. Despite the well-known disadvantages of twin studies they still offer the most direct approach to obtaining an approximate measure of the relative roles of nature and nurture in defining disease phenotypes. And while the role of the environment will vary between different regions, at least this approach will provide some badly needed information about its potential to modify the phenotype.
A more international approach to research in SS disease would also offer the opportunity for learning more about the genetic factors involved in phenotypic diversity. One of the most productive ways of searching for genetic modifiers in murine models of genetic disease is to examine phenotypic modification of single gene disorders bred into different genetic backgrounds, and then to define the genes involved 16 . Sickle cell disease offers a unique opportunity for such studies in humans. As evidenced by -globin-gene haplotype analysis there is clear evidence for multiple origins of the Hb S gene. For example, the form of SS disease which occurs in parts of India and the eastern oasis populations of Saudi Arabia clearly has a different origin to that which predominates throughout the African sub-continent 2, 17 .
While the clinical differences in SS disease between these populations have been reasonably well documented 7 they are by no means all explainable by the known genetic differences between them, notably the level of fetal hemoglobin and the frequency of thalassemia. Indeed, even the reasons for the unusually high levels of Hb F production associated with the Arab/India haplotype have never been While these types of programs have evolved in the thalassemia field over many years 26 this has not been the case for SS disease. As shown in the case of thalassemia, provided the research partnerships are sustainable for at least 5-10 years, they have the added effect of improving the clinical services in the poorer countries. Once a country has developed one or more centers of expertize based on these partnerships, it should then be possible for them to evolve local networks for helping countries in the same region to develop clinical and laboratory services at an improved level 24 . There is already preliminary evidence that it should be possible to develop similar programmes for the study and management of SS disease in Africa 27, 28 .
There are a number of requirements to be met before programs of this type can be instituted. First, scientists in the richer countries must be persuaded of their value, and, through their parent institutions and funding agencies, must be given the For personal use only. on . by guest www.bloodjournal.org From opportunity to take a more global approach to SS disease. Second, these programs must be sustainable over a reasonably long period. Finally, they have to be combined with local public-health and educational developments in the developing countries. These issues, particularly funding, have been discussed in more detail recently 24, 25, 29 . It is particular important that clinical investigators in this field enter into a dialog with national and international funding bodies to encourage the development of these potentially cost-effective partnerships which be of mutual benefit to both developed and developing countries.
Summary
The case for developing scientific partnerships between rich and poor countries to tackle the problems of the natural history and mechanisms for clinical diversity of Hb S disease and related disorders is extremely strong. Building international links of this kind also offers an opportunity to improve clinical services for this distressing disease in the developing world and for minority communities in developed nations.
For these reasons serious consideration should be given to the establishment of partnerships between research centers in the richer countries and those in Africa, the Middle East and India.
